Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Fibrodysplasia Ossificans Progressiva (FOP): full-pipeline trial registry
2 of 3 indexed Fibrodysplasia Ossificans Progressiva (FOP) trials are currently recruiting.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 2 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Fibrodysplasia Ossificans Progressiva (FOP): 3 US clinical trials tracked, 2 recruiting.
Fibrodysplasia Ossificans Progressiva (FOP) is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Incyte Corporation, running 1 of these trials.
Enrollment posture brief
Registry condition fibrodysplasia-ossificans-progressiva-fop
OPEN 2 | RECR 67% | LATE 1 | EARLY 1 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)
Fibrodysplasia Ossificans Progressiva (FOP) lists 2 open slots (67% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Fibrodysplasia Ossificans Progressiva (FOP) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Fibrodysplasia Ossificans Progressiva (FOP) is recruiting above its size-band peers.
2 of 3 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva
Incyte Corporation
NCT05090891
IL1 Inhibition in FOP
University of California, San Francisco
NCT06724562
A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies.
Ipsen
NCT05027802
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Fibrodysplasia Ossificans Progressiva (FOP) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Fibrodysplasia Ossificans Progressiva (FOP) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Fibrodysplasia Ossificans Progressiva (FOP) page
3 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Fibrodysplasia Ossificans Progressiva (FOP) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Incyte Corporation sponsors the most Fibrodysplasia Ossificans Progressiva (FOP) trials on record, review their full trial history before evaluating a specific study. See Incyte Corporation's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Fibrodysplasia Ossificans Progressiva (FOP) condition card totals 3 registered trials; most-linked intervention Palovarotene; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.